Zevra Therapeutics Stock Target Price and Analyst Consensus
| ZVRA Stock | 9.59 0.46 5.04% |
The current analyst and expert consensus on Zevra Therapeutics is Strong Buy, with 4 strong buy opinions. The current projected Zevra Therapeutics target price consensus is 19.25 with 8 analyst opinions. Check out Macroaxis Advice on Zevra Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.The most common way Zevra Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Zevra Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Zevra Therapeutics. We strongly encourage you to use your own analysis of Zevra Therapeutics to validate this buy or sell advice. Zevra Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Zevra Therapeutics target price to derive its highest and lowest estimates based on projected price volatility of 3.3814.
Lowest Forecast 17.52 | Highest Forecast 21.37 | Target Price 19.25 |
Zevra |
It's important to approach Zevra Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Zevra Therapeutics price targets
Zevra Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Zevra Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Zevra Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Zevra Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Zevra Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Zevra Therapeutics is a key component of Zevra Therapeutics valuation and have some predictive power on the future returns of a Zevra Therapeutics.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Entertainment Invested over 90 shares | |
 | Macroaxis Index Invested few shares | |
 | Hedge Favorites Invested over 60 shares | |
 | Impulse Invested over 100 shares | |
 | Banking Invested over 20 shares | |
 | Cash Cows Invested few shares | |
 | Social Domain Invested few shares | |
 | Chemicals Invested over 30 shares | |
 | Business Services Invested few shares | |
 | Macroaxis Picks Invested over 30 shares | |
 | Warren Buffett Holdings Invested over 60 shares | |
Check out Macroaxis Advice on Zevra Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For information on how to trade Zevra Stock refer to our How to Trade Zevra Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Please note, the presentation of Zevra Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zevra Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zevra Therapeutics' management manipulating its earnings.